Market closedADR
BioNTech SE/$BNTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Ticker
$BNTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
6,133
Website
BioNTech SE Metrics
BasicAdvanced
$29B
Market cap
-
P/E ratio
-$2.04
EPS
0.25
Beta
-
Dividend rate
Price and volume
Market cap
$29B
Beta
0.25
52-week high
$121.88
52-week low
$76.53
Average daily volume
986K
Financial strength
Current ratio
7.329
Quick ratio
7.099
Long term debt to equity
1.079
Total debt to equity
1.275
Interest coverage (TTM)
-26.83%
Management effectiveness
Return on assets (TTM)
-1.23%
Return on equity (TTM)
-2.40%
Valuation
Price to revenue (TTM)
9.084
Price to book
1.51
Price to tangible book (TTM)
1.62
Price to free cash flow (TTM)
28.455
Growth
Revenue change (TTM)
-54.07%
Earnings per share change (TTM)
-117.07%
3-year revenue growth (CAGR)
-39.59%
3-year earnings per share growth (CAGR)
-58.88%
What the Analysts think about BioNTech SE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.
BioNTech SE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BioNTech SE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BioNTech SE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BioNTech SE stock?
BioNTech SE (BNTX) has a market cap of $29B as of December 15, 2024.
What is the P/E ratio for BioNTech SE stock?
The price to earnings (P/E) ratio for BioNTech SE (BNTX) stock is 0 as of December 15, 2024.
Does BioNTech SE stock pay dividends?
No, BioNTech SE (BNTX) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next BioNTech SE dividend payment date?
BioNTech SE (BNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioNTech SE?
BioNTech SE (BNTX) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.